Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Problems of iron deficiency and anemia in chronic heart failure (CHF) are discussed in the article. A review of the literature on the epidemiology, etiology and pathogenesis of anemia in this category of patients is presented. Various published data on the effect of anemia on the prognosis of CHF are given. The role of iron deficiency in the development of anemia, the features of its diagnosis and influence on the course of CHF are discussed. The author explains the role of various iron deficiency syndromes in the development of anemia in CHF, suggests a significant predominance of mixed forms of iron deficiency, such as iron deficiency anemia in combination with anemia of chronic disease, which are associated not so much with absolute iron deficiency as with systemic inflammatory response. All the existing approaches to the treatment of iron deficiency and anemia in patients with CHF are presented. The positive and negative results of the use of classical oral iron preparations, intravenous forms,  isolated and combined use of recombinant human erythropoietin are presented. The author discusses the reasons for the failure in the treatment of anemia and the absence of a pronounced effect on the clinical manifestations of CHF in the application of standard approaches in treatment. As a possibility of more effective correction of iron deficiency and anemia in patients with CHF, new preparations of liposomial (sucrosomial) iron for oral administration are offered. The last extremely encouraging clinical results of the use of a new iron formulation in the treatment of iron deficiency and anemia in this group of patients are given.

About the Author

N. I. Stuklov
People’s Friendship University of Russia (RUDN University)
Russian Federation

Nikolai I. Stuklov – MD, PhD, Professor, Chair of Hospital Therapy with Courses of Endocrinology, Hematology and Clinical Laboratory Diagnostics, Medical Institute.

Miklukho-Maklaya ul. 6, Moscow, 117198


1. Stuklov N.I., Alpidovsky V.K., Ogurtsov P.P. Anemia. Clinic, diagnosis and treatment. Textbook for doctors. Moscow: MIA; 2013. (In Russ.) [Стуклов Н.И., Альпидовский В.К., Огурцов П.П. Анемии. Клиника, диагностика и лечение. Учебное пособие для врачей. М.: МИА; 2013].

2. Nutritional anaemias. Report of WHO scientific group. WHO Organ. Tech Rep Ser. 1968;405:5-37.

3. UNICEF, United Nations University, WHO. Iron deficiency anemia: assessments, prevention, and control. A guide for programme managers. Geneva: World Health Organization; 2001.

4. Ezekowitz J.A., McAlister F.A., Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223-5. doi:10.1161/01.CIR.0000052622.51963.FC

5. Vatutin NT, Sklyannaya EV, Kirienko Т.S. Anemia in patients with chronic heart failure. Ukrainskij Kardiologicheskij Zhurnal. 2004; 3: 111-6. (In Russ.) [Ватутин Н.Т., Склянная Е.В., Кириенко Т.С. Анемии у больных с хронической сердечной недостаточностью. Украинский Кардиологический Журнал. 2004;3:111-6].

6. Arutyunov G.P. Anemia in patients with chronic heart failure. Serdechnaja Nedostatochnost'. 2003; 4 (5): 224-8. (In Russ.) [Арутюнов Г.П. Анемия у больных хронической сердечной недостаточностью. Сердечная Недостаточность. 2003;4(5):224-8].

7. Tereshchenko SN, Atroshchenko ES, Uskach TM, Anemia as complication of chronic heart failure: prevalence, treatment, prognosis. Ter Arkh. 2008;80(9):90-5. (In Russ.) [Терещенко С.Н., Атрощенко Е.С., Усач Т.М. и др. Анемия, как осложнение хронической сердечной недостаточности: распространенность, прогноз и лечение. Терапевтический Архив. 2008;9:90-5].

8. Androne A.S., Katz S.D., Lund L. et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226-9. doi:10.1161/01.CIR.0000052623.16194.80

9. Crosato M., Steinborn W., Anker S.D. Anemia in chronic congestive heart failure:frequency, prognosis, and treatment. Heart Fail Monit. 2003;4 (1):2-6.

10. Silverberg D.S., Wexler D., Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4 (6):681-6. Doi:10.1016/S1388-9842(02)00115-0

11. Szachniewicz J., Petruk-Kowalczyk J., Majda J. et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol. 2003;90 (2-3):303-8. Doi:10.1016/S0167-5273(02)00574-0

12. Steinborn W., Doehner W., Anker S.D. Anemia in chronic heard failure frequency, prognostic impact. Clin Neurology. 2003;60 (Suppl. 1):103-7.

13. Shilov AM, Melnik MV, Sarycheva AA Anemia in heart failure. Russian Medical Journal. 2003;11(9):545-8. (In Russ.) [Шилов А.М., Мельник М.В., Сарычева А.А. Анемия при сердечной недостаточности. Русский Медицинский Журнал. 2003;11(9):545-8].

14. Shilov AM, Melnik MV, Retivykh ON, Kim IR. Correction of iron deficiency anemia in chronic heart failure. Russkij Medicinskij Zhurnal. 2005; 19: 1254-7. (In Russ.) [Шилов А.М., Мельник М.В., Ретивых О.Н., Ким И.Р. Коррекция железодефицитной анемии при хронической сердечной недостаточности. Русский Медицинский Журнал. 2005;19:1254-7].

15. Carson J.L., Adamson J.W. Iron deficiency and heart disease:ironclad evidence? Hematology Am Soc Hematol Educ Program. 2010;2010:348-50. doi:10.1182/asheducation-2010.1.348.

16. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-27. doi:10.1016/j.jacc.2008.04.061.

17. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-44. Doi:10.1016/S0735-1097(00)00613-6

18. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure:the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-9. Doi:10.1016/S0735-1097(03)00425-X

19. Provotorov V.M., Avdeeva S.A. Effect of erythropoietin on the clinical course of chronic heart failure in patients with anemia:results of not comparative study. Rational Pharmacotherapy in Cardiology. 2011;7(5):605-8. (In Russ.) [Проворотов В.М., Авдеева С.А. Влияние эритропоэтина на клиническое течение хронической сердечной недостаточности у пациентов с анемией:результаты несравнительного исследования. Рациональная Фармакотерапия в Кардиологии. 2011;7 (5):605-8]. DOI:10.20996/1819-6446-2011-7-5-605-608

20. Charlot M., Torp-Pedersen C., Valeur N., SeibЊk M. Anaemia and Long Term Mortality in Heart Failure Patients:A Retrospective Study. Open Cardiovasc Med J. 2010;4:173-7. doi:10.2174/1874192401004010173.

21. Gregory D.D., Sarnak M.J., Konstam M.A. et al. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. Am J Cardiol. 2003;92 (11):1300-5. 10.1016/j.amjcard.2003.08.011

22. Anand IS. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med. 2005;6 (Suppl 3): 13-21.

23. Elisabet E., Terrovitis J.V., Nanas J.N. Anemia in heart failure should we supplement iron in patients with chronic heart failure? Polskie Archiwum Medycyny Wewnętrznej. 2010;120 (9):354-8.

24. Silverberg D.S., Wexler D., Blum M. et al. The interaction between heart failure, renal failure and ane-mia the cardio-renal anemia syndrome. Blood Purif. 2004;22(3):277-84. DOI: 10.1159/000078698

25. Provorotov VM, Avdeeva S.A. Anemia in patients with chronic heart failure. Klinicheskaja Medicina. 2013; 3: 55-9. (In Russ.) [Проворотов В.М., Авдеева С.А. Анемия у больных хронической сердечной недостаточностью. Клиническая Медицина. 2013;3:55-9].

26. Larina V.N., Bart B.Y., Larin V.G. Clinical significance of anemic syndrome in patients with chronic heart failure. Rational Pharmacotherapy in Cardiology. 2010;6(3):311-317. (In Russ.) [Ларина В.Н., Барт Б.Я., Ларин В.Г. Клиническая значимость анемического синдрома у больных хронической сердечной недостаточностью. Рациональная Фармакотерапия в Кардиологии 2010;6 (3):311-7]. DOI:10.20996/1819-6446-2010-6-3-311-317

27. Reznik EV, Gendlin GE, Storozhakov GI, Volynkina VM Renal hemodynamics in patients with chronic heart failure. Zhurnal Serdechnaja Nedostatochnost'. 2007;8(3):118-25. (In Russ.) [Резник Е.В., Гендлин Г.Е., Сторожаков Г.И., Волынкина В.М. Почечная гемодинамика у больных хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2007;8(3):118-25].

28. Mukhin NA, Moiseev VS, Kobalava ZhD, et al. Cardiorenal interactions: clinical implication and role in pathogenesis of cardiovascular and renal diseases. Ter Arkh. 2004;76(6):39-46. (In Russ.) [Мухин Н.А., Моисеев В.С., Кобалава Ж.Д и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер Архив. 2004;76(6):39-46].

29. Steinborn W., Ponikowski P., Anker S. Anemia and congestive heart failure. Circulation. 2003;108(6):e41-2. Doi: 10.1161/01.CIR.0000084394.37044.E2.

30. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055-9. Doi: 10.1161/01.CIR.103.16.2055

31. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486-91. Doi: 10.1161/01.CIR.0000057810.48709.F6

32. Hallberg L., HulthОn L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr. 2000;71(5):1147-1160.

33. González-Costello J., ComТn-Colet J. Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail. 2010;12(11):1159-62. doi: 10.1093/eurjhf/hfq165.

34. Klip I.T., Comin-Colet J., Voors A.A., et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-82. doi: 10.1016/j.ahj.2013.01.017.

35. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872-80. doi: 10.1093/eurheartj/ehq158.

36. Silagy CA, McNeil JJ, Donnan GA, et al. Advers effects of low-dose aspirine in healthy elderly population. Clin Pharmacol Ther. 1993;54:84-9.

37. Dong F., Zhang X., Culver B., et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release:involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond). 2005;109:277-86. DOI: 10.1042/CS20040278

38. Blayney L., Bailey-Wood R., Jacobs A., et al. The effects of iron deficiency on the respiratory function and cytochrome content of rat heart mitochondria. Circ Res. 1976;39:744-8.

39. Willis W.T., Gohil K., Brooks G.A., Dallman P.R. Iron deficiency: improved exercise performance within 15 hours of iron treatment in rats. J Nutr. 1990;120:909-16.

40. Jankowska E.A., Kasztura M., Sokolski M., et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35 (36):2468-76. doi: 10.1093/eurheartj/ehu235.

41. Cohen-Solal A., Damy T., Terbah M., et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16 (9):984-91. doi: 10.1002/ejhf.139.

42. Núñez J., Domínguez E., Ramón J.M., et al. Iron deficiency and functional capacity in patients with advanced heart failure with preserved ejection fraction. Int J Cardiol. 2016;207:365-7. doi: 10.1016/j.ijcard.2016.01.187.

43. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48 (12):2485-9. DOI: 10.1016/j.jacc.2006.08.034

44. Drozd М., Jankowska E.A., Banasiak W., Ponikowski Р. Iron therapy in patients with heart failure and iron deficiency: review of iron preparations for practitioners. Am J Cardiovasc. Drugs. 2017;17 (3):183-201. doi: 10.1007/s40256-016-0211-2.

45. Yeo T.J., Yeo PSD, Ching-Chiew Wong R., et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure:prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014;16(10):1125-1132. doi: 10.1002/ejhf.161.

46. Núñez J., Comín-Colet J., Miñana G., et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18 (7):798-802. doi: 10.1002/ejhf.513.

47. Rangel I., GonНalves A., de Sousa C., et al. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology. 2014;128 (4):320-6. doi: 10.1159/000358377.

48. Camaschella C. Iron-deficiency anemia. New England journal of medicine. 2015;372:1832-43. doi: 10.1056/NEJMc1507104.

49. Munos M., Garcia-Erce J.A., Remacha A.F. Disorders of iron metabolism. Part II: iron deficiency and iron overload. Jornal of Clinical Pathology. 2011;64:287-96. doi: 10.1136/jcp.2010.086991.

50. Thomas D.V., Hinchliffe R.F., Briggs C., et al. Guideline for the laboratory diagnosis of functional iron deficiency. British Journal of Hematology. 2013;161:639-48. DOI: 10.1111/bjh.12311

51. Moreno Chulilla J.A., Romero ColЗs M.S., GutiОrrez MartТn M. Classification of anemia for gastroenterologists. World J Gastroenterol. 2009;15 (37):4627-37. doi: 10.3748/wjg.15.4627

52. Goddard A.F., James M.W., McIntyre A.S., et al. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60 (10):1309-16. doi: 10.1136/gut.2010.228874.

53. Niehaus E.D., Malhotra R., Cocca-Spofford D., et al. Repletion of iron stores with the use of oral iron supplementation in patients with systolic heart failure. J Card Fail. 2015;21 (8):694-7. doi: 10.1016/j.cardfail.2015.05.006.

54. Palazzuoli A., Silverberg D., Iovine F., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152 (6):1096.e9-1096.e15. DOI: 10.1016/j.ahj.2006.08.005

55. Lewis G.D., Semigran M.J., Givertz M.M., et al. Oral iron therapy for heart failure with reduced ejection fraction:design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail. 2016;9 (5):e000345. doi: 10.1161/CIRCHEARTFAILURE.115.000345.

56. Lewis G.D., Malhotra R., Hernandez A.F., et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017;317(19):1958-66. doi: 10.1001/jama.2017.5427.

57. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48 (6):1225-7. DOI: 10.1016/j.jacc.2006.07.015

58. Toblli J.E., Lombraña A., Duarte P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50 (17):1657-65. DOI: 10.1016/j.jacc.2007.07.029

59. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol. 2008;51 (2):103-12. doi: 10.1016/j.jacc.2007.09.036.

60. Usmanov R.I., Zueva E.B., Silverberg D.S., et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21 (2):236-42.

61. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. doi: 10.1056/NEJMoa0908355.

62. Ponikowski P., Voors A.A., Anker S.D., et al., Authors/Task Force Members and Document Reviewers (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18:891-975. doi: 10.1002/ejhf.592.

63. Eckardt K.U. Cardiovascular risk reduction by early anemia treatment with epoetin beta (CREATE) trial. Nephrol Dial Transplant. 2001;16 (Suppl 2):16-18.

64. Erbayraktar S., Yilmaz O., Gokmen N. et al. Erythropoietin is a multifunctional tissue-protective cytokine. Curr. Hematol. Rep. 2003;2 (6):465-470.

65. Sikole A., Polenakovic M., Spiroska V. et al. Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs. 2002;26 (2):98-102. DOI: 10.1046/j.1525-1594.2002.06839.x

66. Mancini D.M., Katz S.D., Lang C. C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299. Doi: 10.1161/01.CIR.0000044914.42696.6A

67. So Relle R. Erythropoietin-not at the Olympics but maybe for anemic heart failure patients. Circulation. 2003;107 (2):e9004. Doi: 10.1161/01.CIR.0000057701.80262.5C

68. Silverberg D.S., Wexler D., Blum M., et al. The effect of correction of anemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.

69. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron:a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-80. Doi: 10.1016/S0735-1097(01)01248-7

70. Comín-Colet J., Ruiz S., Cladellas M., et al. A pilot evaluation of the long-term effect of combined ther-apy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail. 2009;15:727-35. doi: 10.1016/j.cardfail.2009.05.010.

71. Stuklov N.I., Semenova E.N. Treatment of iron deficiency anemia. What is more important, efficacy or tolerability? Is there an optimal solution. Zhurnal Mezhdunarodnoj Mediciny. 2013; 1 (2): 47-55. (In Russ.) [Стуклов Н.И., Семенова Е.Н. Лечение железодефицитной анемии. Что важнее, эффективность или переносимость? Существует ли оптимальное решение. Журнал Международной Медицины. 2013;1(2):47-55].

72. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126 (17):1981-1989. doi: 10.1182/blood-2015-05-642223.

73. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118(10):1142-7. DOI: 10.1016/j.amjmed.2005.01.065

74. Auerbach M., Adamson J.W. How we diagnose and treat iron deficiency anemia. American journal of hematology. 2016;91:31-8. doi: 10.1002/ajh.24201.

75. Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin‑angiotensin systems. Am J Physiol. 1991;261(5Pt1):e642-666.

76. Tobu M, Iqbal O, Fareed D, et al. Erythropoietin‑induced thrombosis as a result of increased inflam-mation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost. 2004;10:225-32.

77. Tarantino G., Brilli E., Zambito Y., et al. Sucrosomial Iron: A New Highly Bioavaible Oral Iron Supplement. Blood. 2015;126:4561

78. Stuklov N.I. Iron-deficiency syndromes in diseases of the gastrointestinal tract: treatment prospects. Klinicheskaja Medicina. 2016; 94 (6): 410-8. (In Russ.) [Cтуклов Н.И. Железодефицитные синдромы при заболеваниях желудочно-кишечного тракта:перспективы лечения. Клиническая Медицина. 2016;94 (6):410-8]. Doi: 10.18821/0023-2149-2016-94-6-410-418

79. Stuklov NI, Basiladze IG, Pivnik AV, and others. Sideral forte is the first experience of pathogenetic therapy of anemia in inflammatory bowel diseases. Vestnik Poslediplomnogo Medicinskogo Obrazovanija. 2016; 4: 21-30. (In Russ.) [Стуклов Н.И., Басиладзе И.Г., Пивник А.В., и др. Сидерал форте – первый опыт патогенетической терапии анемий при воспалительных заболеваниях кишечника. Вестник Последипломного Медицинского Образования. 2016;4:21-30].

80. Stuklov N.I., Basiladze I.G., Pivnik A.V., et al. Sideral Forte the first experience of 3 month therapy of anemia in inflammatory bowel diseases. Materials of 5-th international multidisciplinary course on iron anemia. Florence, Italy. March 31 April 1, 2017.

81. Mafodda A., Giuffrida D., Prestifilippo A., et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25(9):2779-2786. doi: 10.1007/s00520-017-3690-z.

82. Pisani A. Effect of oral sucrosomial iron versus inravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Materials of 5-th international multidisciplinary course on iron anemia. Florence, Italy. March 31-April1, 2017.

83. Zocca N. Effectiveness of iron therapy with sucrosomial iron in patients with multifactorial anemia. Materials of 5-th international multidisciplinary course on iron anemia. Florence, Italy. March 31-April1, 2017.

84. Marazia S., Loderini S., Magliari F., Sarullo F.M., Di Mauro M. Sucrosomial iron supplementation can be a useful support treatment in patients with heart failure and anemia. Materials of 5-th international multidisciplinary course on iron anemia. Florence, Italy. March 31-April1, 2017.

85. Karavidas A., Trogkanis E., Farmakis D., Papingiotis G., Matzaraki V., Perpinia A., Parissis J. Oral sucrosomial iron in heart failure patients with iron deficiency. Materials of 5-th international multidisciplinary course on iron anemia. Florence, Italy. March 31-April1, 2017.

For citation:

Stuklov N.I. IRON DEFICIENCY AND ANEMIA IN PATIENTS WITH CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2017;13(5):651-660. (In Russ.)

Views: 300

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)